Dr. Patrick C. Ma, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 78
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
PA license MD468236 · OH license 35-087260
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Milton S Hershey Medical Center Hershey, PA
- University Medical Center New Orleans New Orleans, LA
Medical groups
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 78
- Services billed
- 409
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 264 | 70 |
| Established patient office or other outpatient visit, 30-39 minutes | 92 | 41 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 24 | 14 |
| Established patient office or other outpatient visit, 20-29 minutes | 20 | 13 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Hershey, PA | 32 |
| Tagrisso (osimertinib mesylate) | 31 |
| Oxycodone Hcl Other prescribers in Hershey, PA | 21 |
| Furosemide Other prescribers in Hershey, PA | 20 |
| Prednisone Other prescribers in Hershey, PA | 19 |
| Potassium Chloride Other prescribers in Hershey, PA | 19 |
| Alecensa (alectinib hcl) | 18 |
| Gabapentin Other prescribers in Hershey, PA | 18 |
| Prochlorperazine Maleate Other prescribers in Hershey, PA | 16 |
| Levothyroxine Sodium Other prescribers in Hershey, PA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $90.93 in total to this clinician.
| Caris Mpi, Inc. | $90.93 |
|---|
| Food and Beverage | $90.93 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $42,669 in research payments for these studies, mostly to the institutions running them.
- A phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non …
AstraZeneca Pharmaceuticals LP - A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment Wit…
Genmab U.S., Inc. - Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics, Inc. · Active, not recruiting · NCT03785249 - A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic No…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.